Nikhil Wagle

Nikhil Wagle

Auto-generated profile, based on publicly available information

Nikhil Wagle

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2020 in Nature Medicine
Verified
Journal Article
Open access
PDF file
MSMichal Slyper
Michal Slyper
CPCaroline B. M. Porter
Caroline B. M. Porter
OAOrr Ashenberg
Orr Ashenberg
JWJulia Waldman
Julia Waldman
EDEugene Drokhlyansky
Eugene Drokhlyansky
ARAviv Regev
Aviv Regev
Single-cell genomics is essential to chart tumor ecosystems. Although single-cell RNA-Seq (scRNA-Seq) profiles RNA from cells dissociated from fresh tumors, single-nucleus RNA-Seq (snRNA-Seq) is needed to profile frozen or hard-to-dissociate tumors. Each requires customization to different tissue and tumor types, posing a barrier to adoption. Here, we have developed a systematic toolbox for profiling fresh and frozen clinical tumor samples using scRNA-Seq and snRNA-Seq, respectively. We analyzed 216,490 cells and nuclei from 40 samples across 23 specimens spanning eight tumor types of varying tissue and sample characteristics. We evaluated protocols by cell and nucleus quality, recovery rate and cellular composition. scRNA-Seq and snRNA-Seq from matched samples recovered the same cell types, but at different proportions. Our work provides guidance for studies in a broad range of tumors, including criteria for testing and selecting methods from the toolbox for other tumors, thus paving the way for charting tumor atlases.

20 December 2020 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
NTNadine M. Tung
Nadine M. Tung
MRMark E. Robson
Mark E. Robson
SVSteffen Ventz
Steffen Ventz
CSCesar A. Santa-Maria
Cesar A. Santa-Maria
RNRita Nanda
Rita Nanda
JGJudy Garber
Judy Garber
PURPOSE: Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi), is approved for the treatment of human epidermal growth factor receptor 2 (HER2)–negative metastatic breast cancer (MBC) in germline (g) BRCA1/ 2 mutation carriers. Olaparib Expanded, an investigator-initiated, phase II study, assessed olaparib response in patients with MBC with somatic (s) BRCA1/ 2 mutations or g/s mutations in homologous recombination (HR)–related genes other than BRCA1/2. METHODS: Eligible patients had MBC with measurable disease and germline mutations in non- BRCA1/ 2 HR-related genes (cohort 1) or somatic mutations in these genes or BRCA1/ 2 (cohort 2). Prior PARPi, platinum-refractory disease, or progression on more than two chemotherapy regimens (metastatic setting) was not allowed. Patients received olaparib 300 mg orally twice a day until progression. A single-arm, two-stage design was used. The primary endpoint was objective response rate (ORR); the null hypothesis (≤ 5% ORR) would be rejected within each cohort if there were four or more responses in 27 patients. Secondary endpoints included clinical benefit rate and progression-free survival (PFS). RESULTS: Fifty-four patients enrolled. Seventy-six percent had estrogen receptor–positive HER2-negative disease. Eighty-seven percent had mutations in PALB2, s BRCA1/ 2, ATM, or CHEK2. In cohort 1, ORR was 33% (90% CI, 19% to 51%) and in cohort 2, 31% (90% CI, 15% to 49%). Confirmed responses were seen only with g PALB2 (ORR, 82%) and s BRCA1/ 2 (ORR, 50%) mutations. Median PFS was 13.3 months (90% CI, 12 months to not available/computable [NA]) for g PALB2 and 6.3 months (90% CI, 4.4 months to NA) for s BRCA1/ 2 mutation carriers. No responses were observed with ATM or CHEK2 mutations alone. CONCLUSION: PARP inhibition is an effective treatment for patients with MBC and g PALB2 or s BRCA1/ 2 mutations, significantly expanding the population of patients with breast cancer likely to benefit from PARPi beyond g BRCA1/ 2 mutation carriers. These results emphasize the value of molecular characterization for treatment decisions in MBC.

13 May 2020 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
SWSeth A. Wander
Seth A. Wander
OCOfir Cohen
Ofir Cohen
XGXueqian Gong
Xueqian Gong
GJGabriela N. Johnson
Gabriela N. Johnson
JBJorge E. Buendia-Buendia
Jorge E. Buendia-Buendia
NWNikhil Wagle
Nikhil Wagle
Mechanisms driving resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in hormone receptor–positive (HR+) breast cancer have not been clearly defined. Whole-exome sequencing of 59 tumors with CDK4/6i exposure revealed multiple candidate resistance mechanisms including RB1 loss, activating alterations in AKT1, RAS, AURKA, CCNE2, ERBB2, and FGFR2, and loss of estrogen receptor expression. In vitro experiments confirmed that these alterations conferred CDK4/6i resistance. Cancer cells cultured to resistance with CDK4/6i also acquired RB1, KRAS, AURKA, or CCNE2 alterations, which conferred sensitivity to AURKA, ERK, or CHEK1 inhibition. Three of these activating alterations—in AKT1, RAS, and AURKA—have not, to our knowledge, been previously demonstrated as mechanisms of resistance to CDK4/6i in breast cancer preclinically or in patient samples. Together, these eight mechanisms were present in 66% of resistant tumors profiled and may define therapeutic opportunities in patients.Significance: We identified eight distinct mechanisms of resistance to CDK4/6i present in 66% of resistant tumors profiled. Most of these have a therapeutic strategy to overcome or prevent resistance in these tumors. Taken together, these findings have critical implications related to the potential utility of precision-based approaches to overcome resistance in many patients with HR+ metastatic breast cancer.This article is highlighted in the In This Issue feature, p. 1079

1 March 2020 in Annals of Oncology
Verified
Journal Article
Closed access
RBR. Barroso-Sousa
R. Barroso-Sousa
EJE. Jain
E. Jain
OCO. Cohen
O. Cohen
DKD. Kim
D. Kim
JBJ. Buendia-Buendia
J. Buendia-Buendia
NWN. Wagle
N. Wagle

10 February 2020 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
CPCorrie A. Painter
Corrie A. Painter
EJEsha Jain
Esha Jain
BTBrett N. Tomson
Brett N. Tomson
MDMichael Dunphy
Michael Dunphy
RSRachel E. Stoddard
Rachel E. Stoddard
NWNikhil Wagle
Nikhil Wagle

10 December 2018 in Nature Genetics
Verified
Journal Article
Closed access
UNUtthara Nayar
Utthara Nayar
OCOfir Cohen
Ofir Cohen
CKChristian Kapstad
Christian Kapstad
MCMichael S. Cuoco
Michael S. Cuoco
AWAdrienne G. Waks
Adrienne G. Waks
NWNikhil Wagle
Nikhil Wagle